Redeye: AroCell Q2 - First quarter with a positive cash flow
Redeye is encouraged to see AroCell recording its first quarter with a positive cash flow, and the report solidifies our take on the coming quarters. We learn about a coming strategic overview that could entail an acquisition, but nothing concrete has been announced. We leave our base case intact and point to AroCell trading at undeservedly low EV/sales multiples.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/